Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Offers Viable and Effective Alternatives for Nicotine Delivery
Results from second in vivo study of 2018 a success DehydraTECH™ had a 90.2 percent greater absorption rate in the first 10 minutes Clients are improving high-quality products through the enhancement of this drug delivery platform Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a company focused on developing and out-licensing its disruptive drug delivery platform DehydraTECH™, recently announced the results of its second in vivo study of 2018 evaluating this edible technology’s use as a nicotine delivery system (http://cnw.fm/Jm6IN). The study was carried out by a third-party laboratory, which discovered that the absorption of nicotine was significantly greater when delivered…